Nozadze D N, Sergienko I V, Balakhonova T V, Semenova A E, Vlasik T N, Kukharchuk V V
Kardiologiia. 2014;54(3):57-63. doi: 10.18565/cardio.2014.3.57-63.
To compare levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) in blood serum of patients from different cardiovascular risk categories.
Patients from Moscow prospective study database (n = 519) were divided into 4 cardiovascular risk categories according to present clinical recommendations (low, moderate, high, very high). Measurement of Lp-PLA2 concentration (mass) was performed using PLAC Test ELISA Kit. Measurement of Lp-PLA2 activity was made using PLAC Test for Lp-PLA2 Activity. Blood serum levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG), lipoprotein (a) (Lp(a)), high sensitive C-reactive protein (hsCRP) and uric acid were also determined.
Preliminary analysis showed that associations between Lp-PLA2 mass and activity became more obvious in patients not treated with statins and patients without diabetes mellitus. So patients receiving statins and diabetics were excluded from final analysis. Lp-PLA2 mass and activity were lower in low cardiovascular risk category patients. There were no significant differences in Lp-PLA2 mass and activity between patients from moderate, high and very high risk categories. There was moderate correlation between Lp-PLA2 mass and Lp-PLA2 activity (r = 0.38, p < 0.00001). We did not find any correlation between Lp-PLA2 and hsCRP, Lp(a) levels, but detected moderate correlation between Lp-PLA2 mass and activity and TC, LDL-C. We also found a mild positive correlation between Lp-PLA2 mass and HDL-C levels. There was a positive correlation between Lp-PLA2 activity and TG, uric acid and negative correlation between Lp-PLA2 activity and HDL-C levels.
In this group of nondiabetic patients not treated with statins both Lp-PLA2 activity and mass were similarly related to categories of cardiovascular risk.
比较不同心血管风险类别的患者血清中脂蛋白相关磷脂酶A2（Lp-PLA2）的水平。
根据当前临床建议，将来自莫斯科前瞻性研究数据库的患者（n = 519）分为4个心血管风险类别（低、中、高、极高）。使用PLAC Test ELISA试剂盒测定Lp-PLA2浓度（质量）。使用Lp-PLA2活性的PLAC Test测定Lp-PLA2活性。还测定了血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、甘油三酯（TG）、脂蛋白（a）[Lp（a）]、高敏C反应蛋白（hsCRP）和尿酸水平。
初步分析表明，在未接受他汀类药物治疗的患者和无糖尿病的患者中，Lp-PLA2质量与活性之间的关联更为明显。因此，接受他汀类药物治疗的患者和糖尿病患者被排除在最终分析之外。低心血管风险类别的患者Lp-PLA2质量和活性较低。中度、高度和极高风险类别的患者之间，Lp-PLA2质量和活性无显著差异。Lp-PLA2质量与Lp-PLA2活性之间存在中度相关性（r = 0.38，p < 0.00001）。我们未发现Lp-PLA2与hsCRP、Lp（a）水平之间存在任何相关性，但检测到Lp-PLA2质量与活性和TC、LDL-C之间存在中度相关性。我们还发现Lp-PLA2质量与HDL-C水平之间存在轻度正相关。Lp-PLA2活性与TG、尿酸之间存在正相关，与HDL-C水平之间存在负相关。
在这组未接受他汀类药物治疗的非糖尿病患者中，Lp-PLA2活性和质量与心血管风险类别同样相关。
